Top Diversified Bank Stocks To Invest In Right Now

Top Diversified Bank Stocks To Invest In Right Now: Alexza Pharmaceuticals Inc.(ALXA)

Alexza Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. The company?s lead product candidate includes ADASUVE (Staccato loxapine) for the acute treatment of agitation in adults with schizophrenia or bipolar disorder. Its other product candidates under development comprise AZ-007 (Staccato zaleplon), which has completed Phase I clinical trials for the treatment of insomnia; and Staccato nicotine that is in pre-Phase 1 clinical trials to help smokers quit by addressing both the chemical and behavioral components of nicotine addiction by delivering nicotine replacement through inhalation. The company was f ormerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Mountain View, California.

Advisors' Opinion:

• [By Monica Wolfe]

  Alexza Pharmaceuticals (ALXA)

  As Alexza Pharmaceuticals price has continued to stay at a 10-year low price, President and CEO Thomas King decided to increase his holdings in the company.

• [By Roberto Pedone]

  Another under-$10 stock that's starting to move within range of triggering a big breakout trade is Alexza Pharmaceuticals (ALXA), which is focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. This stock hasn't done much so far in 2013, with shares up by just 5.6%.

  If you take a look at the chart for Alexza Phar! maceuticals, you'll notice that this stock has been uptrending strong for the last month, with shares moving higher from its low of $4.23 to its recent high of $5.52 a share. Following that uptrend, shares of ALXA have now started to trend sideways and consolidate between $4.95 on the downside and $5.52 on the upside. Shares of ALXA are now starting to spike within range of triggering a big breakout trade above the upper-end of its recent sideways trading chart pattern.

  Market players should now look for long-biased trades in ALXA if it manages to break out above some near-term overhead resistance levels at $5.40 to $5.52 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 256,570 shares. If that breakout triggers soon, then ALXA will set up to re-test or possibly take out its 52-week high at $6.65 a share, or its next major overhead resistance level at $7.60 a share.

  Traders can look to buy ALXA off weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average at $4.77 a share, or near its 200-day moving average at $4.63 a share. One can also buy ALXA off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Edison Investment Research]

  Alexza's (ALXA) US marketing deal with Teva (TEVA) for Adasuve (orally-inhaled loxapine) enhances the product's US sales prospects given Teva's expertise in the psychiatric and hospital markets. Adasuve is a potentially disruptive new product for acute agitation in schizophrenia or bipolar disorder, given its advantages over existing options (injection/oral/buccal). The investment case is shifting from a development/regulatory play to one of commercial execution by Adasuve's licensees, Teva in the US and Ferrer in Europe.

• [By anandjha89]

  Company like Alexza Pharmaceuticals ! (ALXA). I! t has developed an aerosol delivery system for already-approved drugs, called the Staccato system. The companys first product, ADASUVE was approved in January 2013. It combines a 1974-vintage anti-psychotic drug, loxapine, with the companys new delivery device.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-diversified-bank-stocks-to-invest-in-right-now-2.html